grant

Control of cell wall synthesis and antibiotic tolerance in mycobacteria

Organization UNIVERSITY OF TEXAS ARLINGTONLocation ARLINGTON, UNITED STATESPosted 1 Jun 2020Deadline 31 May 2026
NIHUS FederalResearch GrantFY2024AffectAntibiotic AgentsAntibiotic DrugsAntibioticsAntitubercular DrugsBindingCell Communication and SignalingCell PolarityCell SignalingCell WallCell modelCellular modelDataDependenceDephosphorylationDrug ControlsDrug ScreeningDrug TargetingDrug ToleranceDrugsEffectivenessEnzyme GeneEnzyme PrecursorsEnzymesEventFoundationsFutureGeneralized GrowthGenus MycobacteriumGoalsGrowthIn VitroInfectionIntermediary MetabolismIntracellular Communication and SignalingIsoformsKinasesLeftM smegmatisM tbM tuberculosisM tuberculosis infectionM. smegmatisM. tbM. tb infectionM. tuberculosisM. tuberculosis infectionM.tb infectionM.tuberculosis infectionMTB infectionMeasuresMedicationMetabolicMetabolic ProcessesMetabolismMiscellaneous AntibioticModelingMolecularMolecular InteractionMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsMureinMycobacteriumMycobacterium smegmatisMycobacterium tuberculosisMycobacterium tuberculosis (MTB) infectionMycobacterium tuberculosis infectionOutcomePatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPeptidoglycanPermeabilityPharmaceutical PreparationsPhosphatasesPhosphohydrolasesPhosphomonoesterasesPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferase GenePhosphotransferasesPhysiologicPhysiologicalProcessProenzymesProtein DephosphorylationProtein IsoformsProtein PhosphorylationProteinsRecyclingRegimenRegulationRegulatory ProteinResearchRoleSignal PathwaySignal TransductionSignal Transduction SystemsSignalingSignaling Factor Proto-OncogeneSignaling Pathway GeneSignaling ProteinSiteStressTB drugsTB infectionTB therapyTB treatmentTestingTissue GrowthTransphosphorylasesTuberculosisWorkZymogensanti-TB drugsanti-tuberculosis drugsantibiotic tolerancebiological adaptation to stressbiological signal transductioncellular polaritydesigndesigningdisseminated TBdisseminated tuberculosisdrug candidatedrug/agenteffective therapyeffective treatmentgenetic regulatory proteinhatchingimprovedinfection due to Mycobacterium tuberculosismenmolecular modelingmtbmycobacterialnew drug treatmentsnew drugsnew pharmacological therapeuticnew therapeuticsnew therapynext generation therapeuticsnovel drug treatmentsnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel therapeuticsnovel therapyontogenypatient oriented outcomesreaction; crisisregulatory gene productsocial rolestress responsestress; reactiontolerance to antibioticstolerate antibioticstreat M. tuberculosistreat Mtbtreat Mycobacterium tuberculosistreat tbtreat tuberculosistreatment strategytuberculosis drugstuberculosis infectiontuberculosis therapytuberculosis treatmenttuberculous spondyloarthropathy
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

There is a critical need to understand the regulation of cell wall metabolism in Mycobacterium tuberculosis
because it contributes to antibiotic tolerance, which exacerbates tuberculosis outcomes. The objective of this

proposal is to build a molecular model for how environmental information flows through phosphorylation of three

cell wall regulators to dynamically control cell wall metabolism in mycobacteria. The central hypothesis of this

proposal is that the central regulators of the cell wall during growth also regulate it in stress. This hypothesis is

based on our data that the phosphatase PstP controls growth as well as stress responses, and that the

phosphorylated regulators CwlM and DivIVA are required for growth and antibiotic survival. The rationale for this

research is that a molecular understanding of cell wall regulation will pave the way for better TB drugs.

Aim 1: Determine how the phosphatase PstP orchestrates cell wall metabolism. Our working hypothesis

is that phosphorylation of PstP regulates its activity against cell wall factors and helps coordinate the transition

from growth to stasis. We will: a) determine how PstP phosphorylation is affected by stresses in Mtb; b) identify

the key substrates of PstP and determine the activity of different PstP phospho-isoforms on each substrate; and

c) determine how PstP contributes to antibiotic tolerance in Mtb.

Aim 2: Determine how CwlM regulates multiple peptidoglycan enzymes. Our working hypothesis is that

CwlM is regulated by phosphorylation and recycled peptidoglycan, and in turn regulates peptidoglycan synthesis

at multiple steps. We will: a) identify conditions that alter CwlM’s phosphorylation in Mtb; b) characterize the

effects of CwlM and CwlM~P on the binding and activity of its interaction partner enzymes; and c) Measure and

characterize the function and regulation of the catalytic activity of CwlM.

Aim 3: Determine how DivIVA coordinates polar cell wall metabolism. Our working hypothesis is that DivIVA

activates cell wall precursor enzymes to promote growth, and is regulated by phosphorylation. We will: a)

determine how DivIVA’s phosphorylation is affected by growth and stress conditions in Mtb; b) identify sites on

DivIVA required for its protein interactions, and characterize the phospho-dependence of the interactions; and

c) measure the effects of DivIVA and DivIV~P on the activity of their interaction partners.

Upon completion of this work we expect to have a multi-level molecular model of the signaling pathways

that control cell wall precursor synthesis in mycobacteria. We will characterize the regulation of the phosphatase

PstP, which is a master regulator and a candidate drug target for both antibiotics and anti-tolerance drugs. We

will describe the signaling role of the protein interactions between the intermediate regulators CwlM and DivIVA

and their enzymatic regulatory targets; these interactions are potential targets for anti-tolerance drugs. This work

will lay the groundwork for novel drug screens.

Grant Number: 5R01AI148917-05
NIH Institute/Center: NIH

Principal Investigator: Cara Boutte

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →